Immunoprecise Antibodies Ltd

Immunoprecise Antibodies Ltd(IPA)の株式分析

$2.070

+0.150 (+7.25%)終値時点

Loading chart…
High
2.235
Open
2.000
VWAP
2.10
Vol
2.05M
Mkt Cap
26.05M
Low
2.000
Amount
4.31M
EV/EBITDA, TTM
0.00

MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

バリュエーション指標

The current forward P/E ratio for Immunoprecise Antibodies Ltd (IPA) is -22.40, compared to its 5-year average forward P/E of -3.27.

Forward P/E

Strongly Undervalued
5Y Average P/E
-3.27
Current P/E
-22.40
割高
1.15
割安
-7.69

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
割高
0.00
割安
0.00

Forward P/S

Fair
5Y Average P/S
3.97
Current P/S
4.38
割高
6.59
割安
1.36

Alphio AI Price Scenarios for IPA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%IPA

$0.64

シナリオ価格

B

Base

Base · 50%IPA

$0.64

シナリオ価格

B

Bear

Bear · 25%IPA

$0.59

シナリオ価格

イベントタイムライン

2025-09-03 (ET)

09:27:18

ImmunoPrecise Transforms into MindWalk, Signaling Transition to AI Platform

2025-07-24 (ET)

09:16:13

ImmunoPrecise Antibodies reports LENSai Immunogenicity Screening study results

2025-07-14 (ET)

08:04:09

ImmunoPrecise Antibodies regains compliance with Nasdaq

2025-07-03 (ET)

08:32:16

ImmunoPrecise Antibodies announces new validation study on LENSai

2025-06-24 (ET)

07:31:43

ImmunoPrecise Antibodies provides update on dengue vaccine breakthrough

ニュース

IPA FAQ — answered by Alphio AI

MindWalk Holdings Corp., formerly ImmunoPrecise Antibodies Ltd., is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT technology and the LensAI platform, the Company unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める